Lineage Cell Therapeutics (LCTX) Stock: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.01
-0.02 (-1.94%)
▼
5d:
+0.0%
30d:
-8.18%
90d:
-16.53%
HOLD
MODERATE Confidence
Analysis Updated: Sep 18, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LCTX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.01, which is considered oversold relative to its 30-day fair value range of $1.04 to $1.12.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.50 (+434.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.50 (+434.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.04 -
$1.12
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 434.0% below Wall St target ($5.50)
Trading Range Analysis
30-Day Trading Range
$1.04 -
$1.12
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.16
Current Trend
Strong Uptrend
Technical data as of
Sep 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.10
Wall Street Target
$5.50
(+434.0%)
Revenue Growth (YoY)
-61.3%
Profit Margin
-246.6%
Share & Embed Analysis
Last updated: September 18, 2026 12:12 PM ET
Data refreshes hourly during market hours. Next update: 1:12 PM
Data refreshes hourly during market hours. Next update: 1:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 64 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 51 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
